Cardiovascular Devices: Abbott Vascular Inc.

• Publication date: October 2011

This report is a source for data, analysis and actionable intelligence on the Abbott Vascular Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description, func...

This report is a source for data, analysis and actionable intelligence on the Abbott Vascular Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.

Scope of the Research

- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

Cardiovascular Devices Industry in the United States

Data table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 6
Key Facts 7
Abbott Vascular Inc. - Major Products and Services 8
Abbott Vascular Inc. Pipeline Products by Equipment Type 10
Abbott Vascular Inc. Pipeline Products by Development Stage 12
Abbott Vascular Inc. Pipeline Products by Therapy Area 14
Abbott Vascular Inc. Pipeline Products by Trial Phase 16
Abbott Vascular Inc. Pipeline Products by Milestone Summary 18
Absolute Pro Peripheral Self-Expanding Stent System 20
Product Status 20
Product Description 20
Product Milestone 20
Absolute Pro Peripheral Self-Expanding Stent System Clinical Trial 20
Product Patent Details 23
Absorb 24
Product Status 24
Product Description 24
Absorb Clinical Trial 24
Product Patent Details 28
Acculink Carotid Stent - Low-Risky Patients 28
Product Status 28
Product Description 28
AVJ-09-385 29
Product Status 29
Product Description 30
AVJ-09-385 Clinical Trial 30
Coronary Guidewire 33
Product Status 33
Product Description 33
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 33
Product Status 33
Product Description 34
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 Clinical Trial 34
Product Patent Details 37
Endovascular Guidewire 37
Product Status 37
Product Description 37
Frontline Balloon Dilatation Catheter - Next Generation 38
Product Status 38
Product Description 38
Product Patent Details 38
Herculink Elite Renal Stent System 38
Product Status 38
Product Description 38
Product Milestone 39
Herculink Elite Renal Stent System Clinical Trial 39
MitraClip Device 40
Product Status 40
Product Description 40
Product Milestone 40
MitraClip Device Clinical Trial 41
Product Patent Details 45
Omnilink Elite 48
Product Status 48
Product Description 48
Omnilink Elite Clinical Trial 48
Thinman DES 50
Product Status 50
Product Description 50
XIENCE NANO 50
Product Status 50
Product Description 51
Product Milestone 51
XIENCE NANO Clinical Trial 52
Product Patent Details 53
XIENCE PRIME Everolimus Eluting Coronary Stent System 53
Product Status 53
Product Description 54
Product Milestone 54
XIENCE PRIME Everolimus Eluting Coronary Stent System Clinical Trial 54
Product Patent Details 61
Xience SBA Everolimus Eluting Coronary Stent System 61
Product Status 61
Product Description 61
Product Patent Details 62
ZoMaxx Drug Eluting Coronary Stent System 62
Product Status 62
Product Description 62
ZoMaxx Drug Eluting Coronary Stent System Clinical Trial 62
Abbott Vascular Inc. - Top Competitors 64
Abbott Vascular Inc. - Key Executives 65
Abbott Vascular Inc. - Operations and Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Recent Developments 68
October 27, 2010: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Drug And Non-Drug Eluting Coronary Stents 68
September 16, 2010: Abbott Vascular To Present Data On XIENCE V And Vascular Pipeline At TCT 2010 68
June 11, 2010: Abbott Lays Off 120 Jobs In Temecula, French Valley And Santa Clara, California 68
May 25, 2010: HCRI Expands DAPT Study Into Europe 69
February 26, 2010: NIH Clinical Trial Comparing Two Stroke Prevention Procedures Shows Surgery And Stenting Equally Safe And Effective 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71


List of Tables

Abbott Vascular Inc., Major development 1
Abbott Vascular Inc. Key Pipeline Products by Equipment Type 1
Abbott Vascular Inc. Key Pipeline Products by Therapy Area 1
Abbott Vascular Inc. Key Pipeline Products by Development Stage 1
Abbott Vascular Inc. Key Pipeline Products by Trial Phase 1
Abbott Vascular Inc., Major development 7
Abbott Vascular Inc., Major Products and Services 8
Abbott Vascular Inc. Number of Pipeline Products by Equipment Type 10
Abbott Vascular Inc. Pipeline Products by Equipment Type 11
Abbott Vascular Inc. Number of Pipeline Products by Development Stage 12
Abbott Vascular Inc. Pipeline Products by Development Stage 13
Abbott Vascular Inc. Number of Pipeline Products by Therapy Area 14
Abbott Vascular Inc. Pipeline Products by Therapy Area 15
Abbott Vascular Inc. Number of Pipeline Products by Trial Phase 16
Abbott Vascular Inc. Pipeline Products by Trial Phase 17
Abbott Vascular Inc. Number of Pipeline Products By Milestone Summary 18
Abbott Vascular Inc. Pipeline Products by Milestone Summary 19
Absolute Pro Peripheral Self-Expanding Stent System - Product Status 20
Absolute Pro Peripheral Self-Expanding Stent System - Product Description 20
Absolute Pro Peripheral Self-Expanding Stent System - Product Milestone 20
Absolute Pro Peripheral Self-Expanding Stent System - A Prospective, Non-randomized, Two-arm, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro Peripheral Self-Expanding Stent System and Omnilink Elite Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de November o or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery. CAUTION: The Absolute Pro Peripheral Self-Expanding Stent System and Omnilink Elite Peripheral Balloon-expandable Stent System Are Investigational Devices. Limited by Federal (U.S.) Law to Investigational Use Only. 21
Absolute Pro Peripheral Self-Expanding Stent System - Patent Details 23
Absorb - Product Status 24
Absorb - Product Description 24
Absorb - Comparison Of In Vivo Acute Stent Recoil Between The Bioabsorbable Everolimus-Eluting Coronary Stent And The Everolimus-Eluting Cobalt Chromium Coronary Stent: Insights From The ABSORB And SPIRIT Trials 24
Absorb - ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de November o Native Coronary Artery Lesions 25
Absorb - Bioabsorbable Vascular Solutions (BVS) EECSS First In Man Clinical Investigation: A Clinical Evaluation Of The BVS Everolimus Eluting CSS In The Treatment Of Patients With Single de November o Native Coronary Artery Lesions 27
Absorb - Patent Details 28
Acculink Carotid Stent - Low-Risky Patients - Product Status 28
Acculink Carotid Stent - Low-Risky Patients - Product Description 28
AVJ-09-385 - Product Status 29
AVJ-09-385 - Product Description 30
AVJ-09-385 - Spirit Prime Japan 30
Coronary Guidewire - Product Status 33
Coronary Guidewire - Product Description 33
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Product Status 33
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Product Description 34
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) 34
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Carotid Angioplasty And Stenting Versus Endarterectomy In Asymptomatic Subjects Who Are At Standard Risk For Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease 36
Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Patent Details 37
Endovascular Guidewire - Product Status 37
Endovascular Guidewire - Product Description 37
Frontline Balloon Dilatation Catheter - Next Generation - Product Status 38
Frontline Balloon Dilatation Catheter - Next Generation - Product Description 38
Frontline Balloon Dilatation Catheter - Next Generation - Patent Details 38
Herculink Elite Renal Stent System - Product Status 38
Herculink Elite Renal Stent System - Product Description 39
Herculink Elite Renal Stent System - Product Milestone 39
Herculink Elite Renal Stent System - A Clinical Trial to Assess the Safety and Efficacy of the RX Herculink Elite Renal Stent System for the Treatment of Suboptimal Post-Procedural Percutaneous Transluminal Angioplasty (PTA) in de November o or Restenotic Renal Artery Stenoses in Patients With Uncontrolled Hypertension. 39
MitraClip Device - Product Status 40
MitraClip Device - Product Description 40
MitraClip Device - Product Milestone 40
MitraClip Device - Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVEREST II) and Real World ExpAnded MuLtIcenter Study of the MitraClip System (REALISM). 41
MitraClip Device - A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy. 42
MitraClip Device - A Randomized, Controlled, Multi-center Clinical Trial To Evaluate The Safety And Efficacy Of The MitraClip System In Patients With Moderate To Severe Or Severe Mitral Regurgitation As Compared To Surgical Repair Or Replacement 43
MitraClip Device - Percutaneous Treatment Of The Mitral Regurgitation With The MitraClip System In Patients With Severly Reduced Left Ventricular Function - First European Experience 44
MitraClip Device - Patent Details 45
Omnilink Elite - Product Status 48
Omnilink Elite - Product Description 48
Omnilink Elite - Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions 48
Thinman DES - Product Status 50
Thinman DES - Product Description 50
XIENCE NANO - Product Status 50
XIENCE NANO - Product Description 51
XIENCE NANO - Product Milestone 51
XIENCE NANO - SPIRIT III: A Clinical Evaluation Of The Investigational Device XIENCE V Everolimus Eluting Coronary Stent System (EECSS) In The Treatment Of Subjects With de November o Native Coronary Artery Lesions 52
XIENCE NANO - Patent Details 53
XIENCE PRIME Everolimus Eluting Coronary Stent System - Product Status 53
XIENCE PRIME Everolimus Eluting Coronary Stent System - Product Description 54
XIENCE PRIME Everolimus Eluting Coronary Stent System - Product Milestone 54
XIENCE PRIME Everolimus Eluting Coronary Stent System - A Prospective, Multi-center, Non-randomized Trial To Study XIENCE PRIME 54
XIENCE PRIME Everolimus Eluting Coronary Stent System - DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis 55
XIENCE PRIME Everolimus Eluting Coronary Stent System - A Randomized Comparison of the NEVO Sirolimus-eluting Coronary Stent System Using a Bioresorbable Polymer Versus the Everolimus-eluting Coronary Stent System (XIENCE V/XIENCE PRIME/PROMUS) Using a Durable Polymer in Coronary Artery Lesions 56
XIENCE PRIME Everolimus Eluting Coronary Stent System - Evaluation of XIENCE PRIME Everolimus Eluting Stent System (EECSS) or XIENCE V EECSS Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 57
XIENCE PRIME Everolimus Eluting Coronary Stent System - Comparison Of Biolimus-Eluting Biodegradable Polymer, Everolimus-Eluting And Sirolimus-Eluting Coronary Stents 60
XIENCE PRIME Everolimus Eluting Coronary Stent System - Patent Details 61
Xience SBA Everolimus Eluting Coronary Stent System - Product Status 61
Xience SBA Everolimus Eluting Coronary Stent System - Product Description 61
Xience SBA Everolimus Eluting Coronary Stent System - Patent Details 62
ZoMaxx Drug Eluting Coronary Stent System - Product Status 62
ZoMaxx Drug Eluting Coronary Stent System - Product Description 62
ZoMaxx Drug Eluting Coronary Stent System - A Randomized, Controlled Trial To Evaluate The Safety And Efficacy Of The ZoMaxx Drug Eluting Coronary Stent System Compared To The TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in de November o Coronary Artery Lesions 62
Abbott Vascular Inc., Key Executives 65
Abbott Vascular Inc., Other Locations 66


List of Figures

Abbott Vascular Inc. Key Pipeline Products by Equipment Type 1
Abbott Vascular Inc. Pipeline Products by Equipment Type 10
Abbott Vascular Inc. Pipeline Products by Development Stage 12
Abbott Vascular Inc. Pipeline Products by Therapy Area 14
Abbott Vascular Inc. Pipeline Products by Trial Phase 16
Abbott Vascular Inc. Pipeline Products by Milestone Summary 18

Companies mentioned Poly-Med, Inc.
Accumed Systems Inc.
Cordis Corporation
Cardia, Inc
BioTex, Inc.